Group 1 (PSADT >3 months, DM absent at start of SADT) (n = 62) | Group 2 (PSADT <3 months, DM absent at start of SADT) (n = 28) | Group 3 (DM present at start of SADT) (n = 32) | Group 4 (No SADT) (n = 50) | ||
---|---|---|---|---|---|
Age at SRT (y), median (IQR) | 65.7 (58.9–70.4) | 63.0 (56.6–67.3) | 63.6 (57.8–67.6) | 62.3 (55.9–67.5) | p = 0.38* |
CCMI, median (range) (n = 147) | 3.0 (1.0–6.0) | 3.0 (1.0–6.0) | 3.0 (1.0–5.0) | 3.0 (1.0–5.0) | p = 0.49* |
Pre-SRT PSA (ng/mL), median (IQR) (n = 163) | 0.9 (0.5–1.7) | 1.0 (0.5–1.5) | 0.6 (0.3–1.0) | 0.5 (0.4–0.7) | p = 0.09* |
SRT dose (Gy), median (IQR) (n = 171) | 68.4 (64.8–68.4) | 65.8 (64.8–68.4) | 68.4 (64.8–68.4) | 64.9 (64.8–68.4) | p = 0.22* |
WPRT | 11.3% | 3.6% | 12.5% | 8.0% | p = 0.60** |
ADT during SRT | 12.9% | 25.0% | 12.5% | 12.0% | p = 0.40** |
Duration of ADT during SRT (mo), median (IQR) | 6.4 (6.0–19.6) | 6.2 (3.6–11.1) | 6.0 (3.6–7.8) | 6.0 (3.0–12.0) | p = 0.43* |
Gleason score (n = 171) | |||||
2–6 | 9.8% | 7.1% | 3.1% | 22.0% | p = 0.04** |
7 | 63.9% | 42.9% | 53.1% | 54.0% | p = 0.30** |
8–10 | 26.2% | 50.0% | 43.8% | 24.0% | p = 0.04** |
pT stage (n = 146) | |||||
T1-T2a | 10.4% | 0.0% | 3.3% | 4.7% | p = 0.26** |
T2b-T2c | 18.8% | 12.0% | 16.7% | 16.3% | p = 0.91** |
T3-T4 | 70.8% | 88.0% | 80.0% | 79.1% | p = 0.39** |
SVI (n = 171) | 21.0% | 35.7% | 34.4% | 26.5% | p = 0.38** |
ECE | 54.8% | 78.6% | 75.0% | 70.0% | p = 0.07** |
SM (n = 169) | 38.7% | 53.6% | 53.3% | 36.7% | p = 0.28** |
Undetectable PSA nadir post-SRT (n = 170) | 69.4% | 64.3% | 81.30% | 45.8% | p = 0.008** |
PSA before SADT (ng/mL), median (IQR) | 4.3 (2.0–6.7) | 2.7 (1.0–8.0) | 5.2 (2.4–9.7) | --- | p = 0.21* |
PSADT after SRT (mo), median (IQR) | 6.0 (4.5–9.5) | 2.2 (1.5–2.7) | 4.1 (1.9–7.3) | 27.0 (13.6–47.7) | p < 0.001* |
IBF (mo), median (mean) | 12.9 (18.1) | 11.5 (18.5) | 13.6 (13.8) | 48.3 (48.7) | p < 0.001* |
IBF <18 months | 61.3% | 67.9% | 75.0% | 12.0% | p < 0.0001** |